Neurological disease drug developer Axial raised $37.3m from investors including Taiho Ventures while Best Buy is purchasing OSF and Legal & General-backed remote healthcare technology provider Current Health.


US-based neurological disease therapy developer Axial Therapeutics closed a $37.3m series C round yesterday featuring Taiho Ventures, the investment arm of pharmaceutical firm Taiho. The round was co-led by OneVentures and University of Tokyo’s Innovation Platform Company and included Autism Impact Fund, Corundum Systems Biology, Longwood Fund, Seventure Partners and Domain Associates. Axial has now raised $91.5m in total, Taiho Ventures having put up $10m to close a series B round featuring care provider Heritage Medical Systems, Health for…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.